Design of a potent interleukin-21 mimic for cancer immunotherapy A de novo IL-21 mimic, 21h10, exhibits improved stability and potent antitumor activity in vivo compared with native IL-21.

David Baker & colleagues develop an #IL21 mimic (21h10) that is more stable & shows x-reactivity against both human & murine #IL21R. 21h10 promotes potent antitumor responses in mice and in human #melanoma tumor explants, expanding low-affinity CD8 #TCells & #TH1 cells & reducing #Tregs in #tumors!